COVIVAXX – a new COVID-19 vaccine under development
COVIVAXX is a new vaccine candidate to protect against COVID-19. Developed by the Serum Institute of India Pvt. LTD (SIIPL), the globally leading vaccine manufacturer, VPM coordinates the clinical development in Europe. A phase I/II trial is currently ongoing in Australia to assess the safety and immunogenicity of COVIVAXX in humans. A pivotal phase III trial is planned to be conducted in Europe and India in the first half of 2021. Click here to read more.